openPR Logo
Press release

Acute Kidney Injury Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | AM-Pharma, Alexion, Alloksys, Aptabio Therapeutics, ArchBiopartners, Novartis, Ocelot Bio, River2Renal, Sentien

02-23-2024 02:18 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Acute Kidney Injury Pipeline Assessment Covering Clinical

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the Acute Kidney Injury therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Acute Kidney Injury Pipeline Insight" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Acute Kidney Injury Therapeutics Market.

The report provides a detailed description of the Acute Kidney Injury drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Acute Kidney Injury Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Kidney Injury Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Acute Kidney Injury therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Kidney Injury treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Acute Kidney Injury drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Acute Kidney Injury treatment market.

Learn More about the Clinical and Commercial Development Activities in the Acute Kidney Injury Therapeutics Domain @
https://www.delveinsight.com/report-store/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Kidney Injury Therapeutics Analysis
Roughly 30+ prominent pharma and biotech companies are actively engaged in developing therapies for Acute Kidney Injury (AKI). Among the leading players, AM-Pharma Holding stands out for having advanced AKI drug candidates in phase III clinical trials. Companies operating in the market collectively represent a diverse spectrum of approaches and innovations aimed at addressing the challenges posed by AKI, a serious medical condition. Their dedication to advancing treatments underscores the urgent need for effective interventions to improve outcomes for patients suffering from AKI.

Acute Kidney Injury Companies in the Therapeutics Market Include:
Some of the key companies in the Acute Kidney Injury Market include AM-Pharma Holding, Alexion Pharmaceuticals, Alloksys Life Sciences, Aptabio Therapeutics, ArchBiopartners, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Faron Pharmaceuticals, Guard Therapeutics, Kantum Pharma, Metro International Biotech, LLC, Novartis Pharmaceuticals, Ocelot Bio, Rediscovery Life Sciences, Renibus Therapeutics, Revelation Biosciences, River2Renal Corp., Sentien Biotechnologies, and others.

Emerging and Marketed Acute Kidney Injury Therapies Covered in the Report Include:
• Ilofotase alfa: AM-Pharma Holding
• SBI 101: Sentien Biotechnologies
• RMC-035: Guard Therapeutics AB
• RBT-1: Renibus Therapeutics
• OCE-205: Ocelot Bio
And Many More

Get an in-depth Assessment of the Emerging Therapies and Acute Kidney Injury Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Acute Kidney Injury Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Acute Kidney Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Request for Sample PDF to Understand More About the Acute Kidney Injury Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Acute Kidney Injury Current Treatment Patterns
4. Acute Kidney Injury - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Acute Kidney Injury Late-Stage Products (Phase-III)
7. Acute Kidney Injury Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Kidney Injury Discontinued Products
13. Acute Kidney Injury Product Profiles
14. Acute Kidney Injury Companies
15. Acute Kidney Injury Drugs
16. Dormant and Discontinued Products
17. Acute Kidney Injury Unmet Needs
18. Acute Kidney Injury Future Perspectives
19. Acute Kidney Injury Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Kidney Injury Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | AM-Pharma, Alexion, Alloksys, Aptabio Therapeutics, ArchBiopartners, Novartis, Ocelot Bio, River2Renal, Sentien here

News-ID: 3397345 • Views:

More Releases from DelveInsight Business Research LLP

Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials, and Companies 2024 (Updated)
Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials, and Companies 2024 (Upda …
DelveInsight's, "Ewing Sarcoma Pipeline Insights 2024" report provides comprehensive insights about 25+ Ewing Sarcoma companies and 25+ pipeline drugs in the Ewing Sarcoma pipeline landscape. It covers the Ewing Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ewing Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials, and Companies 2024 (Updated)
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials, and C …
DelveInsight's, "Diffuse Intrinsic Pontine Glioma Pipeline Insight 2024" report provides comprehensive insights about 25+ Diffuse Intrinsic Pontine Glioma companies and 25+ pipeline drugs in the Diffuse Intrinsic Pontine Glioma pipeline landscape. It covers the Diffuse Intrinsic Pontine Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Intrinsic Pontine Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights
Parkinson's Disease Pipeline, FDA Approvals, Clinical Trials and Companies 2024 (Updated)
Parkinson's Disease Pipeline, FDA Approvals, Clinical Trials and Companies 2024 …
DelveInsight's, "Parkinson's Disease Pipeline Insight 2024" report provides comprehensive insights about 140+ Parkinson's Disease companies and 150+ pipeline drugs in Parkinson's Disease pipeline landscape. It covers the Parkinson's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from
Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials, and Companies 2024 (Updated)
Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials, and Companies 2024 (U …
DelveInsight's, "Multiple Myeloma Pipeline Insights 2024" report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from

All 5 Releases


More Releases for Acute

Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but
Pipeline Review, H2 2017 of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
"Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- '
Acute Renal Failure (ARF) (Acute Kidney Injury) Market: Industry Size, Share, Gr …
Latest industry research report on: Acute Renal Failure (ARF) (Acute Kidney Injury) Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape. Request For Sample Report
Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H2
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230595 Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood.
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth